The global HIV Diagnostics Market size was estimated at USD 3.2 billion in 2021, growing at a CAGR of 9.8% during the forecast period 2021-2027. Acquired immune deficiency syndrome (AIDS) is a retroviral infectious disease caused by human immunodeficiency virus (HIV). HIV attacks the body immune system ideally CD4 cells (T cells), which helps the immune system to fight infections. HIV spreads through body fluids i.e. blood donation and imparting needles to somebody who is HIV infected, and sexual interactions. If HIV is not treated the opportunistic infections like tuberculosis or cancer take advantage of very weak immune system and causes AIDS. The HIV Diagnostics Market can be done by viral load test, saliva test, and blood test. Most accurate test results can obtained by enzyme linked immunosorbent assay (ELISA) test initial stages and western blot method on later stages. Currently, there was no effective cure exists for HIV, but with proper medical care, it can be controlled. Global HIV diagnosis market is growing at steady state. Government and non-government organizations are also participating in creating and growing awareness related to early HIV diagnosis and available diagnostic tests and equipment. According to WHO, 2015, there is 0.8% prevalence of HIV globally and Sab-Saharan Africa remains most severely affected area with 70% of people for global population. For instance, the unmet requirements in Asia and Africa region for HIV diagnosis, and the government initiatives taken in the region may drive the market for HIV diagnostics. Market players adopting mergers and acquisitions to increase the market position in HIV diagnostics market. In addition, market has a number of pipeline products in accurate and quick diagnosis of HIV few of them are Visitect CD4, Chipcare CD4, and MBIO CD4. Antibody diagnosis test is predominant among the segments. Due to the introduction of point of care products can easily and quickly diagnose disease.